Medicare spells out what the new Alzheimer's drug registries will collect
As part of efforts to improve access to drugs that may slow the progression of Alzheimer’s disease, Medicare reiterated that it will cover new anti-amyloid drugs with full or traditional approval, and now it’s spelling out how it wants real-world data to be collected to study the usefulness of these drugs.
Eisai and Biogen’s Leqembi (lecanemab) is likely to be the first of the amyloid-targeted monoclonal antibodies to win full approval, with a PDUFA date of July 6. That full approval will set off almost immediate coverage from CMS, increasing access for the first time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
